On January 6, the U.S. Food and Drug Administration (FDA) granted the first waiver to allow a nucleic acid-based test, the Alere i Influenza A & B test, to be used in a greater variety of healthcare settings. The test uses a nasal swab sample from a patient and provides results in as little as 15 minutes. Negative results don’t rule out influenza virus infection. Read more.